DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

Botanical Bounty: Cracking the Herbal Medicine Market Enigma and Growth Potential

Herbal Medicine, rooted in ancient traditions across cultures worldwide, has witnessed a remarkable evolution in the modern era. The global Herbal Medicine Market has experienced significant growth over the years, fueled by a resurgence of interest in natural remedies and a growing awareness of the potential health benefits offered by botanical extracts. From traditional herbal preparations to standardized extracts and modern formulations, the market has expanded to cater to diverse consumer needs and preferences. Herbal Medicine offers a plethora of benefits, including holistic approaches to health, reduced side effects compared…

Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisition; Novartis’ Fabhalta CHMP Approval; Idorsia’s TRYVIO FDA Approval; AbbVie’s Landos Biopharma Acquisition

Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), each occurring after two or more lines of systemic therapy. The sole concern for approval is associated with the status of enrollment in the confirmatory trials. The CRLs, one for R/R FL and one for R/R DLBCL did not highlight any concerns regarding…

Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology

Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation of blisters even from minor friction or injury. This disorder arises from genetic changes that impact the proteins crucial for upholding the skin’s structural strength. The degree of severity in epidermolysis bullosa can vary significantly, spanning from mild forms to those posing life-threatening risks, contingent upon the particular subtype. Blistering that occurs in any type of epidermolysis bullosa can lead to further problems such as infection, sepsis, and even death. Infants with severe forms of…

Bristol Myers Squibb’ Karuna Therapeutics Buyout; Orchard Therapeutics’ Lenme...

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared…

Find out more
Promising Nephrotic Syndrome Treatments: A Look into the Future

Nephrotic syndrome is a clinical condition characterized by significant protein in the urine (exceeding 40…

Find out more
Unveiling the Potential of TROP-2 Inhibitors: A New Frontier in Cancer Treatment

Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of…

Find out more
Allumiqs and Prolytix’s Partnership; Setpoint Medical’s Neuroimmune Mod...

MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy…

Find out more
Telemedicine Service: Delving into Opportunities and Key Growth Factors Drivi...

Telemedicine Services have emerged as a transformative force in healthcare delivery, offering remote diagnosis, consultation,…

Find out more
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive ...

BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared…

Find out more
voquezna-for-gerd-treatment
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Find More
recent-developments-in-nsclc-treatment
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Find More
Rehabilitation Equipment Market Analysis
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone ...

Find More
Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More

See How We Do It

Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.